Al-Mondhiry H, Pierce WS, Basarab RM. Protamine-induced thrombocytopenia and leukopenia. Thromb Haemost 53:60-64,1985.

Amiral J, Bridey F, Dreyfus M, Vissac AM, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin induced thrombocytopenia [letter]. Thromb Haemost 68:95-96, 1992.

Amiral J, Bridey F, Wolf M, Boyer-Neumann C, Fressinaud E, Vissac AM, Peynaud-Debayle E, Dreyfus M, Meyer D. Antibodies to macromolecular platelet factor 4 heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 73:21-28,1995.

Amiral J, Marfaing-Koka A, Wolf M, Alessi MC, Tardy B, Boyer-Neumann C, Vissac AM, Fressinaud E, Poncz M, Meyer D. Presence of auto-antibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated-thrombocytopenia. Blood 88:410-416,1996a.

Amiral J, Peynaud-Debayle E, Wolf M, Bridey F, Vissac AM, Meyer D. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low molecular weight heparin. Am J Hematol 52:90-95,1996b.

Amiral J, Wolf M, Fischer AM, Boyer-Neumann C, Vissac AM, Meyer D. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 92:954-959, 1996c.

Amiral J, Pouplard C, Vissac AM, Walenga JM, Jeske W, Gruel Y. Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation. Br J Haematol 109:336-341, 2000.

Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocyto-penia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 98:1252-1254, 2001.

Arepally G, McKenzie SE, Jiang X-M, Poncz M, Cines DB. FcyRIIA H/R131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood 89:370-375,1997.

Aziz KA, Cawley JC, Zuzel M. Platelets prime PMN via released PF4: mechanism of priming and synergy with GM-CSF. Br J Haematol 91:846-853,1995.

Bachelot-Loza C, Saffroy R, Lasne D, Chatellier G, Aiach M, Rendu F. Importance of the FcyRIIA-Arg/His-131 polymorphism in heparin-induced thrombocytopenia diagnosis. Thromb Haemost 79:523-528, 1998.

Bacsi S, De Palma R, Visentin GP, Gorski J, Aster RH. Complexes of heparin and platelet factor 4 specifically stimulate T cells from patients with heparin-induced thrombocytopenia/thrombosis. Blood 94:208-215, 1999.

Bauer TL, Arepally G, Konkle BA, Mestichelli B, Shapiro SS, Cines DB, Poncs M, McNulty S, Amiral J, Hauck WW, Edie RN, Mannion JD. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 95:1242-1246, 1997.

Barber AJ, Käser-Glanzmann R, Jakabova M, Lüscher F. Characterization of a chon-droitin 4-sulfate proteoglycan carrier for heparin neutralizing activity (platelet factor 4) released from human blood platelets. Biochim Biophys Acta 286:312-329, 1972.

Bendtzen K, Hansen MB, Ross C, Poulsen LK, Svenson M. Cytokines and autoantibo-dies to cytokines. Stem Cells 13:206-222, 1995.

Blank M, Shoenfeld Y, Tavor S, Praprotnik S, Boffa MC, Weksler B, Walenga MJ, Amiral J, Eldor A. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 14:121-129, 2002.

Bock PE, Luscombe M, Marshall SE, Pepper DS, Holbrook JJ. The multiple complexes formed by the interaction of platelet factor 4 with heparin. Biochem J 191:769-776, 1980.

Boshkov LK, Warkentin TE, Hayward CPM, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 84:322-328, 1993.

Brandt E, Flad HD. Structure and function of platelet-derived cytokines of the jg-thromboglobulin/interleukin 8 family. Platelets 3:295-305,1992.

Brandt J, Isenhart CE, Osborne JM, Ahmed A, Anderson CL. On the role of platelet FcyRIIa phenotype in heparin-induced thrombocytopenia. Thromb Haemost 74:1564-1572,1995.

Burgess JK, Lindeman R, Chesterman CN, Chong BH. Single amino acid mutation of Fcy receptor is associated with the development of heparin-induced thrombocytope-nia. Br J Haematol 91:761-766, 1995.

Bux-Gewehr I, Helmling E, Sefert UT. HAT type II and platelets within a normal range. Kardiologia 85:656-660,1996.

Capitanio AM, Niewiarowski S, Rucinski B, Tuszynski GP, Cierniewski CS, Hershock D, Kornecki E. Interaction of platelet factor 4 with human platelets. Biochim Biophys Acta 839:161-173, 1985.

Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 316:581-589, 1987.

Cowan SW, Bakshi EN, Machin KJ, Isaacs NW. Binding of heparin to human platelet factor 4. Biochem J 234:485-488,1986.

Denomme GA, Warkentin TE, Horsewood P, Sheppard JI, Warner MN, Kelton JG. Activation of platelets by sera containing IgGl heparin-dependent antibodies: an explanation for the predominance of the FcyRIIa "low responder" (his131) gene in patients with heparin-induced thrombocytopenia. J Lab Clin Med 130:278-284, 1997.

Dunlop MG, Prowse CV, Dawes J. Heparin-induced platelet factor 4 release in patients with atherosclerotic peripheral vascular disease. Thromb Res 46:409-410, 1987.

Francis JL. Detection and significance of heparin-platelet factor 4 antibodies. Semin Hematol 42 (3 suppl 3):S9-S14, 2005.

Greinacher A. Heparin-induced thrombocytopenia: frequency and pathogenesis. Patho-physiol Haemost Thromb 35:37-45, 2006.

Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Hae-most 71:247-251, 1994.

Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 74:886-892, 1995.

Gruel Y, Boizard-Boval B, Wautier JL. Further evidence that a-granule components such as platelet factor 4 are involved in platelet-IgG-heparin interactions during heparin-associated thrombocytopenia. Thromb Haemost 70:374-375,1993.

Gruel Y, Pouplard C, Lasne D, Magdelaine-Beuzelin C, Charroing C, Wautier H. The homozygous FcyRIIIa-158V genotype is a risk factor for heparin-induced thrombo-cytopenia in patients with antibodies to heparin-platelet factor 4 complexes. Blood 104:2791-2793, 2004.

Hach-Wunderle V, Kainer K, Krug B, Müller-Berghaus G, Pötzsch B. Heparin-associated thrombosis despite normal platelet counts. Lancet 344:469-470, 1994.

Harenberg J, Malsch R, Piazolo L, Heene DL. Binding of heparin to human leukocytes. Hamostaseologie 14:16-24,1994.

Hérault JP, Lalé A, Savi P, Pflieger AM, Herbert JM. In vitro inhibition of heparin-induced platelet aggregation in plasma from patients with HIT by SR 121566, a newly developed Gp IIb/IIIa antagonist. Blood Coagul Fibrinolysis 8:206-207,1997.

Horne MK III, Alkins BR. Platelets binding of IgG from patients with heparin-induced thrombocytopenia. J Lab Clin Med 127:435-442, 1996.

Horne MK III, Chao ES. Heparin binding to resting and activated platelets. Blood 74: 238-243, 1989.

Horne MK III, Chao ES. The effect of molecular weight on heparin binding to platelets. Br J Haematol 74:306-312, 1990.

Horne MK III, Hutchison KJ. Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia. Am J Hematol 58:24-30, 1998.

Huang SS, Huang JS, Deul TS. Proteoglycan carrier of platelet factor 4. J Biol Chem 257:11546-11550, 1982.

Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol 95:161-167,1996.

Jeske WP, Walenga JM, Szatkowski E, Ero M, Herbert JM, Haas S, Bakhos M. Effect of glycoprotein IIb-IIIa antagonists on the HIT serum induced activation of platelets. Thromb Res 88:271-281, 1997.

Jy W, Mao WW, Horstman LL, Tao J, Ahn YS. Platelet microparticles bind, activate and aggregate neutrophils in vitro. Blood Cells Mol Dis 21:217-231,1995.

Kelton J. Pathophysiology of heparin-induced thrombocytopenia [letter]. Br J Haematol 82:778-784, 1992.

Kelton JG, Sheridan D, Santos A, Smith J, Steeves K, Smith C, Brown C, Murphy WG. Heparin-induced thrombocytopenia: laboratory studies. Blood 72:925-930, 1988.

Kelton JG, Smith JW, Warkentin TE, Hayward CPM, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 83:3232-3239, 1994.

Li ZQ, Liu W, Park KS, Sachais BS, Arepally GM, Cines DB, Poncz M. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood 99:1230-1236, 2002.

Lindahl U, Lidholt K, Spillmann D, Kjellen L. More to "heparin" than anticoagulant. Thromb Res 75:1-32, 1994.

Lindhoff-Last E, Gerdsen F, Ackermann H, Bauersachs R. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocy-topenia. Br J Haematol 113:886-890, 2001.

Luscombe M, Marshall SE, Pepper D, Holdbrook JJ. The transfer of platelet factor 4 from its proteoglycan carrier to natural and synthetic polymers. Biochim Biophys Acta 678:137-142, 1981.

Maccarana M, Lindahl U. Mode of interaction between platelet factor 4 and heparin. Glycobiology 3:271-277, 1993.

Marcus AJ, Safier LB, Broekman MJ, Islam N, Fliessbach JH, Hajjar KA, Kaminski WE, Jendraschak E, Silverstein RL, von Schacky C. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Thromb Haemost 74:213-217,1995.

Meyer O, Aslan T, Koster A, Kiesewetter H, Salama A. Report of a patient with heparin-induced thrombocytopenia type II associated with IgA antibodies only. Clin Appl Thromb Hemost 12:373-375, 2006.

Nash GB. Adhesion between neutrophils and platelets: a modulator of thrombotic and inflammatory events? Thromb Res 74:S3-S11,1994.

Nesmelova IV, Sham Y, Dudek AZ, van Eijk LI, Wu G, Slungaard A, Mortari F, Griffioen AW, Mayo KH. Platelet factor 4 and interleukin-8 CXC chemokine hetero-dimer formation modulates function at the quaternary structural level. J Biol Chem 280:4948-4958, 2005.

Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 80:292-297, 1998.

Petersen F, Lidwig A, Flad HD, Brandt E. TNF-a renders human neutrophils responsive to platelet factor 4. J Immunol 156:1954-1962, 1996.

Polgar J, Eichler P, Greinacher A, Clemetson KJ. Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients. Blood 91:549-554, 1998.

Poncz M. Mechanistic basis of heparin-induced thrombocytopenia. Semin Thorac Cardiovasc Surg 17:73-79, 2005.

Pouplard C, Amiral J, Borg JY, Vissac AM, Delahousse B, Gruel Y. Differences in specificity of heparin-dependent antibodies developed under low-molecular-weight-heparin therapy and higher cross-reactivity with Orgaran. Br J Haematol 99: 273-280, 1997.

Pouplard C, Iochmann I, Renard O, Hérault O, Colombat P, Amiral J, Gruel Y. Induction of monocyte tissue factor expression by antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia. Blood 97:3300-3302, 2001.

Rauova L, Poncz M, McKenzie SA, Reilly MP, Arepally G, Weisel JW, Nagaswami C, Cines DB, Sachais BS. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 105:131-138, 2005.

Regnault V, de Maistre E, Carteaux JP, Gruel Y, Nguyen P, Tardy B, Lecompte T. Platelet activation induced by human antibodies to interleukin-8. Blood 101: 1419-1421, 2003.

Reilly MP, Taylor SM, Franklin C, Sachais BS, Cines DB, Williams KJ, McKenzie SE. Prothrombotic factors enhance heparin-induced thrombocytopenia and thrombosis in vivo in a mouse model. J Thromb Haemost 4:2687-2694, 2006.

Reininger CB, Greinacher A, Graf J, Lasser R, Steckmeier B, Schweiberer L. Platelets of patients with peripheral arterial disease are hypersensitive to heparin. Thromb Res 81:641-649, 1996.

Reitamo S, Remitz A, Varga J, Ceska M, Effenberger F, Jimenez S, Uitto J. Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders. Arch Dermatol 129:189-193, 1993.

Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 136:210-215, 2002.

Rubinstein E, Boucheix C, Worthington RE, Carroll RC. Anti-platelet antibody interactions with Fcy receptor. Semin Thromb Hemost 21:10-22,1995.

Rybak ME, Gimbrone MA, Davies PF, Handin RI. Interaction of platelet factor four with cultured vascular endothelial cells. Blood 73:1534-1539, 1989.

Schattner M, Lazzari M, Trevani AS, Malchiodi E, Kempfer AC, Isturiz MA, Geffner JR. Activation of human platelets by immune complexes prepared with cationized human IgG. Blood 82:3045-3051, 1993.

Shoenfeld Y. Heparin-induced thrombocytopenia as an autoimmune disease: idiotypic evidence for the role of anti-heparin-PF4 autoantibodies. Isr J Med Sci 33:243-245, 1997.

Slungaard A. Platelet factor 4: a chemokines enigma. Int J Biochem Cell Biol 37: 1162-1167, 2005.

Smythe MA, Stephen JL, Mattson JC. Delayed-onset heparin-induced thrombocytopenia. Ann Emerg Med 45:417-419, 2005.

Sobel M, Adelman B. Characterization of platelet binding of heparins and other glycosaminoglycans. Thromb Res 50:815-826,1988.

Stuckey JA, St Charles R, Edwards B. A model of the platelet factor 4 complex with heparin. Proteins 14:277-287, 1992.

Suh JS, Malik MI, Aster RH, Visentin GP. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol 54:196-201, 1997.

Suh JS, Aster RH, Visentin GP. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. Blood 91:916-922, 1998.

Suvarna S, Rauova L, McCracken EKE, Goss CM, Sachais BS, McKenzie SE, Reilly MP, Gunn MD, CInes DB, Poncz M, Arepally G. PF4/heparin complexes are T cell-dependent antigens. Blood 106:929-931, 2005.

Sylvester L, Yoshimura T, Sticherling M, Schroder JM, Ceska M, Peichi P, Leonard EJ. Neutrophil attractant protein-1-immunoglobulin G immune complexes and free anti-NAP-1 antibody in normal human serum. J Clin Invest 90:471-481, 1992.

Van Rijn JLML, Trillou M, Mardiguian J, Tobelem G, Caen J. Selective binding of heparins to human endothelial cells. Implications for pharmacokinetics. Thromb Res 45:211-222, 1987.

Visentin GP, Aster RH. Heparin induced thrombocytopenia and thrombosis. Curr Opin Hematol 2:351-357,1995.

Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 93:81-88, 1994.

Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: platelet factor 4 complexes. J Lab Clin Med 128:376-383, 1996.

Warkentin TE. Heparin-induced thrombocytopenia. Diagnosis and Management. Circulation 110:454-458, 2004.

Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytope-nia. Chest 127:35-45, 2005.

Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 101:502-507, 1996.

Warkentin TE, Sheppard JA. Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev 20:259-272, 2006.

Warkentin TE, Hayward CPM, Boshkov LK, Santos AV, Sheppard JI, Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84:3691-3699,1994.

Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332:1330-1335, 1995.

Warkentin TE, Sheppard JI, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 146:341-346, 2005.

Warkentin TE, Sheppard JI, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 108:2937-2941, 2006a.

Warkentin TE, Jay RM, Makris M, Kelton JG. Platelet-activating anti-platelet factor 4/ polyanion antibodies without preceding heparin therapy: a transient autoimmune disorder resembling heparin-induced thrombocytopenia ("spontaneous HIT") [abstr]. Blood 108:311a-312a, 2006b.

Ziporen L, Li ZQ, Park KS, Sabnekar P, Liu WY, Arepally G, Shoenfeld Y, Kieber-Emmons T, Cines DB, Poncz M. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 92:3250-3259, 1998.

0 0

Post a comment